Clinilabs Achieves Mortara Certified Partner Status
Clinilabs, Inc., a specialty contract research organization (CRO), is now a Mortara Certified Partner capable of collecting, processing, and transmitting annotated ECG data compliant with ECG Warehouse requirements.
Clinilabs Achieves Mortara Certified Partner Status
New York, NY (July 25, 2008) – Clinilabs, Inc., a specialty contract research organization (CRO), is now a Mortara Certified Partner capable of collecting, processing, and transmitting annotated ECG data compliant with ECG Warehouse requirements. The Clinilabs ECG Core Laboratory and integrated cardiac safety unit provide state-of-the-art facilities in support of ECG intensive and thorough QT (TQT) studies, operating to the standard required for upload of datasets into the FDA’s ECG Warehouse.
With Mortara Certified Partner status, Clinilabs has a competitive advantage in serving sponsors, and is now among the world’s leading vendors of ECG services. Sponsors that choose Clinilabs as their ECG Core Lab are assured of exceptional service and minimal risk of study failure.
“As a Mortara-certified ECG Core Laboratory, Clinilabs is poised to provide sponsors with the same world-class quality in ECG data management that both large pharmaceutical and biotechnology companies have grown accustomed to receiving from us as a core lab in the CNS arena since 2002,” stated Dr. Gary Zammit, Clinilabs’ President and CEO.
Developed in association with the FDA, the Mortara ECG Warehouse offers tools for uploading annotated ECGs with the Agency capable of efficient review, scoring, and warehousing.
About Clinilabs, Inc.
Clinilabs is a specialty contract research organization (CRO) that provides a full portfolio of services to pharmaceutical, biotechnology, and medical device companies involved in the development of central nervous system (CNS) and cardiovascular (CV) therapeutics. The Company also provides early phase services in a wider range of therapeutic areas at its Phase I facility. Established in 2001, Clinilabs has provided services to more than one third of the world’s top 20 pharmaceutical companies, and has been involved in 7 successful New Drug Applications (NDAs) in central nervous system (CNS) and cardiovascular (CV) indications. For more information, please visit www.clinilabs.com.
About Mortara Instrument
Mortara Instrument, Inc, based in Milwaukee, WI, is distinguished in the field of non-invasive cardiology for innovations that are the core of the company’s complete line of ECG products including electrocardiographs, stress exercise systems, Holter systems and data warehousing solutions, and cardiology monitoring systems. The Company’s website is www.mortara.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
